SEC Form 4 · accession 0001209191-17-019177
KUBOTA PHARMACEUTICAL HOLDINGS CO LTD · M??????
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Feb 28, 2017
Accepted (ET)
Mar 8, 2017 · 1:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001400482
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 28, 2017 | J | 6,196,869 | $49,711,631.43 | D | 0 | D | |
| Common StockF2,F3 | Feb 28, 2017 | J | 6,196,869 | $49,711,631.43 | A | 14,486,625 | I | By SBI Incubation Co., Ltd. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Intra-company transfer from SBI Holdings, Co. Ltd. to SBI Incubation Co., Ltd. SBI Incubation Co., Ltd. is an indirect wholly-owned subsidiary of SBI Holdings, Inc.
- F2The shares were purchased at a price of 5,589,575,838 Japanese Yen. The purchase price reported above is reflected in US Dollars, based on the Mizuho TTM rate in effect on the date of purchase, rounded to the nearest whole cent.
- F3These shares are held directly by SBI Incubation Co., Ltd. SBI Holdings, Inc. may be deemed to be the indirect beneficial owner of these securities.